Literature DB >> 19997894

[Clostridium difficile-associated infections. How dangerous are the new strains?].

A Kola1.   

Abstract

In recent years, a global increase of Clostridium difficile-associated infections (CDI) and the emergence of new hypervirulent strains causing numerous outbreaks was noticed. The appearance of these strains was accompanied by increased morbidity and mortality, affecting patients previously unknown to be at risk for CDI. Meanwhile, these hypervirulent strains occur in Germany as well. So far, the changing epidemiology of CDI did neither change diagnosis nor therapy of CDI but necessitates a series of preventive measures like the surveillance of CDI and contact precautions while caring for affected patients. If there are complicated or severe cases of CDI, the hypervirulent strains should be suspected and stool culture for isolation of C. difficile should be aimed.

Entities:  

Mesh:

Year:  2010        PMID: 19997894     DOI: 10.1007/s00108-009-2416-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

2.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

4.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

5.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

6.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors:  J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

Review 7.  Implications of the changing face of Clostridium difficile disease for health care practitioners.

Authors:  Lynne V McFarland; Henry W Beneda; Jill E Clarridge; Gregory J Raugi
Journal:  Am J Infect Control       Date:  2007-05       Impact factor: 2.918

8.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Authors:  E J Kuijper; F Barbut; J S Brazier; N Kleinkauf; T Eckmanns; M L Lambert; D Drudy; F Fitzpatrick; C Wiuff; D J Brown; J E Coia; H Pituch; P Reichert; J Even; J Mossong; A F Widmer; K E Olsen; F Allerberger; D W Notermans; M Delmée; B Coignard; M Wilcox; B Patel; R Frei; E Nagy; E Bouza; M Marin; T Akerlund; A Virolainen-Julkunen; O Lyytikäinen; S Kotila; A Ingebretsen; B Smyth; P Rooney; I R Poxton; D L Monnet
Journal:  Euro Surveill       Date:  2008-07-31

9.  Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates.

Authors:  F Barbut; P Mastrantonio; M Delmée; J Brazier; E Kuijper; I Poxton
Journal:  Clin Microbiol Infect       Date:  2007-09-11       Impact factor: 8.067

Review 10.  New trends in Clostridium difficile virulence and pathogenesis.

Authors:  C Denève; C Janoir; I Poilane; C Fantinato; A Collignon
Journal:  Int J Antimicrob Agents       Date:  2009-03       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.